NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9).

Members Present: Kelley Burnett, D.O.; Walter Hardin, D.O., MBA; Tracy Klein, PhD, FNP; Phillip Levin, PhD; Caryn Mickelson, PharmD; William Origer, MD;

Members Present by Phone: Stacy Ramirez, PharmD; James Slater, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Trevor Douglass, DC, MPH; Renae Wentz, MD; Jonnaliz Corbett, Dee Weston, Dana Hargunani, MD, MPH

Staff Present by Phone: Kathy Sentena, PharmD

Audience: Tim McFerron, Alkermes; Paul Thompson, Alkermes; Laura Jeffcoat, Abbvie; *Maggi Olmon, Abbvie; Amy Burns, AllCare; Lisa Boyle, WVP Health; *Steve Nemirow, Kartini Clinic; *Kent Benner, MD, The Oregon Clinic; *Lorren Sandt, Caring Ambassadors; *Andrew Seaman, Central City Concern/OHSU; *Beth Englander, OLC; *BJ Cavnor, One in Four; Michelle Bree, Gilead; Troy McGrow, Gilead; Jake Mazzola, AllCare; Leo Yesinki, Merck; Dawn Bina, Novo Nordisk; Steve Hill, Relypsa; Mike Willett, Pfizer; Troy Larson, Sage; Jean Harris, Novo Nordisk; Stephanie Lattig, Novo Nordisk; *Dr. Tony Hoovler, Novo Nordisk; Jeana Colabianchi, Sunovion; *Valerie Ng, Indivior; Dr. Danielle Shannan, WVP Health; Mary Kemhus, Novartis; Ted Raszka, Sanofi; Paul Bonham, Avexis; Georgette Dewilewsa, Indivior; Jaimie Vickery, Cure SMA; Bill McDougall, Biogen; *Lynda Finch, Biogen; Mark Helm, CHAOS

(*) Provided verbal testimony

Written testimony provided: Posted to OSU Website
I. CALL TO ORDER

A. The meeting was called to order at approximately 1:02 pm. Introductions were made by Committee members and staff. No new conflicts of interest were declared.

B. Approval of agenda and September 2018 minutes presented by Mr. Citron.
   a. Mr. Citron proposed to move Nusinersen: OHA SMARTEN Participation as the final topic of business and approve September 2018 meeting minutes

   ACTION: Motion to approve, 2nd, all in favor

C. Dr. Dana Hargunani presented certificates of appreciation to departing members of the Pharmacy and Therapeutics Committee, Dr. Phil Levine, Dr. Rich Clark and Dr. Walter Hardin. Beginning in January, Dr. Jim Rickards and Dr. Mark Helm with join the committee.

D. Dr. Trevor Douglass anticipates finalizing the approval process for one more committee member by December 2018.

II. CONSENT AGENDA TOPICS

A. Long-Acting Insulins DERP Summary
   Dr. Walter Hardin raised a concern regarding the DERP report, as it fails to include the preferred NPH insulin for type 1 and type 2 diabetics due to its low cost compared to alternatives. Additionally, Canadian research indicated the difference is not clinically significant. Dr. Hardin suggests this should be an option based on evidence. Additionally, the DERP reports give OHA relative risk reduction without absolute risk reduction, so there isn’t a way of knowing the magnitude of reporting. Dr. Hardin is not proposing any changes but would like OHA to provide this feedback to DERP.

B. Humira® (adalimumab) Indication Review for Hidradenitis Suppurativa

C. Quarterly Utilization Reports

   ACTION: Motion to approve items A-C and provide comments made by Dr. Hardin in the minutes, 2nd, all in favor

III. DUR ACTIVITIES

A. ProDUR Report - Mr. Holsapple presented the ProDUR report

B. RetroDUR Report - Dr. Engen presented the RetroDUR report

C. Oregon State Drug Reviews
   1. Update on Treatment options for Moderate to Severe Atopic Dermatitis
   2. Management Strategies for Patients with Prediabetes

   Dr. Sentena presented two recently published newsletters, thanked the Committee for reviewing the draft versions and solicited ideas for future newsletters.

IV. PREFERRED DRUG LIST NEW BUSINESS

A. Severe Acne Class Review
   Dr. Moretz presented the proposal to:
   Implement prior authorization (PA) criteria for the Acne PDL class, to limit use to funded conditions and to designate at least one formulation of the following medications/classes as
a preferred agent on the PDL due to guideline support for use in severe acne: oral isotretinoin, topical benzoyl peroxide, topical retinoid (adapalene or tretinoin), and topical antibiotics

**ACTION:** Motion to approve, 2nd, all in favor

B. Hepatitis C Direct Acting Antivirals Policy Discussion
Dr. Servid presented the proposal to amend the PA criteria to expand access by removing fibrosis restrictions. The Committee amended the proposed PA criteria to: simplify the language in question 2a to only require a diagnosis of chronic hepatitis C infection (B18.2); modify the language in 4a to say “genotype testing in the past 3 years is required if the patient has cirrhosis, any prior treatment experience, or if prescribed a regimen which is not pan-genotypic”; remove requirement for documentation of HIV status, but add a note that HIV testing is recommended; and simplify the language in 4g to state “presence or absence of cirrhosis as clinically determined (e.g., clinical, laboratory or radiologic evidence)”.

**ACTION:** Motion to approve, 2nd, all in favor

C. Orilissa™ (elagolix) New Drug Evaluation
Dr. Engen presented the proposal to create a new PDL class for gonadotropin-releasing hormone (GnRH) receptor antagonists and implement prior authorization criteria for elagolix.

**ACTION:** Motion to approve, 2nd, all in favor

---

### V. DUR OLD BUSINESS

A. Nusinersen: OHA SMARTEN Participation

**ACTION:** No action, deferred topic

B. Growth Hormone Prior Authorization Criteria Update
Dr. Servid presented the proposal to update the PA criteria as presented to align with the Health Evidence Review Commission (HERC) coverage guidance.

**ACTION:** Motion to approve, 2nd, all in favor

C. Testosterone Prior Authorization Criteria Update
Dr. Servid presented the proposal to update the PA criteria as presented to align with HERC coverage guidance

**ACTION:** Motion to approve, 2nd, all in favor

---

### VI. DUR NEW BUSINESS

A. Substance Use Disorder Class Update/Drug Use Evaluation

**ACTION:** No action, deferred topic

---

### VII. EXECUTIVE SESSION

**Members Present:** Kelley Burnett, D.O.; Walter Hardin, D.O, MBA; Tracy Klein, PhD, FNP; Phillip Levin, PhD; Caryn Mickelson, PharmD; William Origer, MD;
**Members Present by Phone:** Stacy Ramirez, PharmD; James Slater, PharmD

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Trevor Douglass, DC, MPH; Renae Wentz, MD; Jonnaliz Corbett, Dee Weston, Dana Hargunani, MD, MPH

**Staff Present by Phone:** Kathy Sentena, PharmD

---

**VIII. RECONVENE FOR PUBLIC RECOMMENDATIONS  * After executive session**

A. **Long-Acting Insulins Drug Effectiveness Review**  
   **Recommendation:** The Committee recommended making no changes to the PMPDP.

B. **Severe Acne Class Review**  
   **Recommendation:** The Committee recommended making all single source brand (SSB) agents in the Acne PMPDP class non-preferred and all other agents in the Acne PMPDP class preferred.

C. **Hepatitis C Direct Acting Antivirals Policy Discussion**  
   **Recommendation:** The Committee recommended upon expansion to lower stages of fibrosis, to limit the use of Zepatier and Epclusa to patients where Mavyret would not be appropriate.

**ACTION:** Motion to approve items A-C, 2nd, all in favor

---

**VIII. ADJOURN**